ACT1_3A | R Documentation |
Kaplan-Meier digitized data from ACT1, figure 3A (PMID 25385727). A reported sample size of 637 for a primary endpoint of OS in lung cancer.
ACT1_3A
A data frame of 637 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (amrubicin, topotecan) | |
von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9.
summary(ACT1_3A)
kmplot(ACT1_3A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.